Medical Device Weekly Highlights (Mar 23–29, 2026): IPO Filings, Strategic M&A, and Regulatory Advances

Recently, Xinfazhan Company, a subsidiary of Shanghai Waigaoqiao Group, signed a contract with leading brain-computer interface company Canopy Technology. The latter will establish a Shanghai Clinical and Product Engineering Center to promote the transition of brain-computer interface technology from laboratory to clinical application in the Yangtze River Delta region. Canopy Technology focuses on non-invasive brain-computer interface technology and achieves non-invasive deep brain stimulation through time-domain interference technology, opening up new pathways for the treatment of neuropsychiatric diseases. Its founding team has been deeply engaged in the field of deep brain stimulation for many years, accumulating a large amount of data, building technological barriers, possessing a multi-dimensional patent system, and demonstrating broad application prospects. Currently, Canopy Technology’s products have submitted an application for Breakthrough Therapy Designation to the U.S. FDA and received a formal response, as well as securing nearly 100 million yuan in A+ round financing. After this signing, Canopy Technology will establish a clinical center relying on Shanghai's clinical resources and utilize Yangtze River Delta resources to build a product R&D and engineering center.

Recently, during the 6th Global Investment Partners Conference of the 2026 Beijing Daxing International Airport Aerotropolis (Daxing), three major life and health projects were simultaneously launched. The International Regenerative Medicine Industrial Park focuses on cutting-edge areas such as cell and gene therapy to create a green innovation hub. The Grena High-end Medical Device Logistics Project establishes a healthcare industry hub, while Xinyi Zhipu advances the R&D and clinical transformation of ultrasound AI to enhance the smart healthcare industry chain. Each project contributes from different sectors, strongly supporting the construction of a regional life and health industry cluster and promoting international industrial expansion. Currently, the Daxing area of the Aerotropolis has initially formed an industrial development pattern with "core track leadership and supporting facilities," covering cutting-edge fields like cell and gene therapy, artificial intelligence + healthcare, and deploying multiple core industry platforms such as high-end medical logistics and advanced medical equipment. The trend of collaborative industrial development is becoming increasingly evident.

It was reported that the 23rd China International Medical Laboratory Diagnostics and Blood Transfusion Instrument Reagent Expo (CACLP) was held in Xiamen from March 21 to 23. During the conference, Wondfo Biotech unveiled three new products: LA-6400, LA-2000, and FC-6100, comprehensively showcasing its rich innovative achievements and multi-scenario solutions in the in vitro diagnostics field. The new product launch event was packed with attendees, drawing significant attention as numerous industry experts and partners gathered to exchange ideas. Addressing the industry pain points of limited laboratory space in outpatient and emergency departments and constrained budgets for medium and small-sized hospitals, Wondfo Biotech introduced the LA-6400 Integrated Sample Processing System. With a compact size of just 0.9 square meters, this system features a highly integrated design, enabling efficient operation by one or two people through centralized single-screen control. It significantly reduces spatial and labor costs, transforming from a split setup to an integrated solution and simplifying complex processes, making the LA-6400 a standout highlight at the event.

On March 18, Mindray Medical announced its entry into the U.S. ventilator market by launching two critical care ventilators, the SV900 and SV700, to compete with giants such as GE Healthcare and Philips. This move represents a validation of Mindray's systematic capabilities, shifting its overseas strategy from "emerging market expansion" to "developed market penetration," and from "price competition" to "product and system competition," emphasizing a "critical care product portfolio." The core selling points of the SV900 and SV700 are their "multi-functional integration," combining invasive ventilation, non-invasive ventilation, and high-flow oxygen therapy, enhancing clinical workflow efficiency while reducing hospital procurement and maintenance costs. However, the U.S. market has high entry barriers, and Mindray faces challenges in channels and service systems, brand and clinical trust, as well as procurement and bundled capabilities. Entering the U.S. ventilator market is essentially a test of its global operational capabilities.

Recently, the Center for Medical Device Evaluation of the National Medical Products Administration released the Guiding Principles for Registration Review of X-ray Blood Irradiation Equipment on its website. The Guiding Principles aim to guide registration applicants in preparing and drafting registration application materials for X-ray blood irradiation equipment, while also providing reference for technical review departments during the examination of registration application materials. The X-ray blood irradiation equipment referred to in the Guiding Principles are medical devices that utilize an X-ray source to irradiate blood samples such as bagged whole blood, red blood cells, and platelets. Equipment using other radiation sources for blood sample irradiation, such as gamma-ray sources, may also refer to these principles.

Recently, the Heilongjiang Provincial Department of Industry and Information Technology and the Heilongjiang Provincial Department of Finance jointly released five policy implementation rules, including: "Detailed Implementation Rules of Heilongjiang Province's Policy on Rewards for Supporting New Drug and High-End Medical Device R&D Innovation," "Detailed Implementation Rules of Heilongjiang Province's Policy on Rewards for Supporting the Transformation and Application of New Drugs and High-End Medical Devices," "Detailed Implementation Rules of Heilongjiang Province's Policy on Rewards for Supporting Secondary Development of Major Traditional Chinese Medicine Varieties," "Detailed Implementation Rules of Heilongjiang Province's Policy on Rewards for Supporting Centralized Bulk Procurement of Pharmaceuticals and Medical Devices," and "Detailed Implementation Rules of Heilongjiang Province's Policy on Rewards for Supporting the Promotion of Pilot Platform Services in Biomanufacturing." The aim is to accelerate the high-quality development of Heilongjiang’s biopharmaceutical and biomanufacturing industries, as well as to expedite the R&D innovation and transformation application of high value-added innovative products.

Recently, the National Medical Products Administration (NMPA) announced the launch of the "Spring Rain Initiative" to promote the clinical innovation and transformation of medical device achievements, deciding to implement the three-year "Spring Rain Initiative" across China. The initiative aims to advance source innovation in medical devices guided by clinical value, focusing on the integration of medicine and engineering to facilitate the transformation of clinical innovation achievements. The overall requirement is to implement relevant opinions by establishing a mechanism for "collection and screening—matching—mentoring and cultivation—transformation implementation," building an innovative ecosystem, streamlining transformation pathways, fostering the market entry of landmark products that integrate medicine and engineering, and meeting clinical needs. Tasks include collecting and screening high-quality projects, with each provincial bureau establishing collection channels and formulating screening plans to identify projects with clinical application value, innovation, and feasibility for transformation; matching medical device companies for registration research, with each provincial bureau establishing a matching mechanism to promote two-way selection between medical and engineering fields, following up on project progress, and implementing dynamic management and exit mechanisms.

Recently, the National Medical Products Administration (NMPA) released several IVD industry standards, introducing updated and more detailed requirements for the clinical trial management of IVD reagents and the establishment of enterprise reference materials. These new standards primarily focus on the standardized management of clinical trials and the setup of product quality control materials. For IVD companies preparing for product registration applications, it is crucial to thoroughly understand and implement these standards. The IVD industry standards include "Requirements for the Management of Biological Samples in Clinical Trials of In Vitro Diagnostic Reagents," "Requirements for Setting Enterprise Reference Materials for Qualitative Diagnostic Test Systems," and "General Quality Requirements for Clinical Trials of In Vitro Diagnostic Reagents." The implementation date for all three standards is March 1, 2027.

Recently, the 2026 Suzhou Business Conference was held in Suzhou. As a significant event marking the starting point of the "15th Five-Year Plan," the conference released the "List of Key Emerging and Future Industries in Suzhou" and the "Suzhou Action Plan for Building a First-Class Business Environment (2026)." The ten key emerging industries include: biomedicine and high-end medical devices, artificial intelligence, semiconductors and integrated circuits, nanomaterials, high-end instrumentation and intelligent testing equipment, embodied intelligent robots and integrated machine tool equipment, photonics and light manufacturing, smart connected new energy vehicles, advanced photovoltaics and new energy storage, and low-altitude economy. The ten key future industries include: commercial aerospace, bio-manufacturing, cell and gene technology, 6G equipment and applications, quantum technology, embodied intelligence, hydrogen energy and next-generation nuclear energy equipment, brain-computer intelligence, frontier new materials, and atomic-level manufacturing.

Recently, the Hainan Provincial Drug Administration issued the "Hainan Province Medical Device Enterprise Risk Self-Inspection Work Guidelines" aimed at providing precise guidance and standardized services to enhance enterprises' compliance management levels, and to build a safety defense line for the high-quality development of the medical device industry in the Hainan Free Trade Port. The "Guidelines" are based on the actual development of the medical device industry in the Hainan Free Trade Port, systematically arranging around seven aspects, covering the entire chain, with a focus on key links such as the quality management system, clarifying the requirements for risk closed-loop management, and providing enterprises with a clear path and practical operational guidance for self-inspection. In addition, the "Guidelines" highlight five major principles, clearly defining the self-inspection responsibilities of different entities, detailing the triggering scenarios, time limits, and work processes for annual and special inspections, guiding enterprises to proactively identify risks and make timely corrections, promoting quality management towards "active prevention and control" and "pre-event prevention."

Recently, the State Administration for Market Regulation released the "Deployment of Key Legislative Tasks for 2026".The Medical Device Administration Law has been included in the key legislative projects for 2026. Previously, the State Administration for Market Regulation clearly stated that it would promote the formulation and revision of regulations such as the Food Safety Law and the Medical Device Administration Law. In September 2023, the Medical Device Administration Law was included in the legislative plan, and in 2024, the National Medical Products Administration completed the "Draft Submission of the Medical Device Administration Law." Now, the State Administration for Market Regulation has officially assigned the relevant legislative tasks. The "Draft for Public Comment of the Medical Device Administration Law" consists of eleven chapters and 190 articles, covering all aspects of medical device research, production, operation, use, and more.

Recently, the Medical Device Standards Management Center of the National Medical Products Administration, at the request of the National Medical Products Administration, organized the drafting of two draft guidelines for public comment related to brain-computer interface medical devices. These are the "Guiding Principles for the Classification of Medical Device Products Using Brain-Computer Interface Technology (Draft for Public Comment)" and the "Guiding Principles for the General Naming of Medical Devices Using Brain-Computer Interface Technology (Draft for Public Comment)." These two guiding principles aim to standardize medical devices using brain-computer interface technology and are currently open for public comment to further improve relevant standards and promote the scientific, rational application and development of brain-computer interface technology in the field of medical devices.

Recently, the Shandong Provincial Drug Administration issued the "2026 Provincial Medical Device Vigilance Pilot and Registrant Adverse Event Monitoring Inspection Plan," making comprehensive arrangements for the inspection of medical device vigilance pilots and registrant adverse event monitoring. The "Inspection Plan" specifies the scope, content, responsibilities, timeline, and other aspects of inspections for adverse events and vigilance pilots of medical devices across the province. It identifies 47 medical device vigilance pilot registrants as key inspection targets and requires all relevant units to fulfill their functions, coordinate with annual inspection and sampling plans, and collaboratively advance the implementation of inspection tasks.。

According to the announcement "Further Clarification of Relevant Requirements for Radio Frequency Treatment Device Products" (No. 84 of 2024) issued by the National Medical Products Administration (NMPA), radio frequency beauty devices must obtain a Class III medical device certification. The NMPA announcement clearly states that, starting from April 1, 2026, the production, import, and sale of radio frequency treatment devices and radio frequency skin treatment devices without legally obtained medical device registration certificates will be prohibited. These products were originally scheduled to be regulated as Class III medical devices starting from April 1, 2024, but due to various factors, the implementation of the new regulations has been postponed until now. Under the enforcement of the new regulations, the radio frequency beauty device market is facing entirely new challenges. Meanwhile, the home-use beauty device market is also undergoing changes. Previously experiencing rapid growth, it is now being accompanied by increased regulatory scrutiny to ensure compliance. Obtaining Class III medical device certification requires significant financial investment and lengthy clinical trials, and more than 90% of small and medium-sized brands, as well as generic brands, may face elimination.